Tazbentetol
AssetAlso SPG302
Oral transient activator of glutamatergic synapses promoting synaptic regeneration
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 3
- Indications
- 5
- Trials
- 1
- Developer
Indications
3ALS
Phase 2, spinogenix.com, 7 Oct 2026
Alzheimer's disease
Phase 2, Active not recruiting, NCT06427668, clinicaltrials.gov, 7 Oct 2026
Amyotrophic lateral sclerosis
Phase 2, Terminated, NCT06903286, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Owner and partners1
- Trials5
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.